Clovis Oncology Co-338-087- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study In Ovarian Cancer Patients Evaluating Rucaparib And Nivolumab As Maintenance Treatment Following Response To Front-Line Platinum-Based Chemotherapy)
Posted Date: Nov 22, 2019
- Investigator: Caroline Billingsley
- Specialties: Cancer, Gynecologic Oncology, Oncology, Ovarian Cancer
- Type of Study: Drug
The goal of this study is to evaluate progression free survival, overall response rate, and duration of response of patients using Rucaparib and Nivolumab after responding to Platinum-Based Chemotherapy.
Criteria:
To Be Eligible: 18 Yrs Or Older, Diagnoses Of Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer, No Active Second Malignancy Within 3 Years, Nonpregnant/Breastfeeding, No Active Or Uncontrolled Medical Disorder, Disease, Or Infection Making Them A Poo
Keywords:
Ovarian Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com